News & Views | Published:

Out of harm's way

Nature Biotechnology volume 29, pages 4142 (2011) | Download Citation

Screening for safe harbor sites in the genome may improve the safety of gene therapy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Nat. Biotechnol. 29, 73–78 (2011).

  2. 2.

    et al. PLoS ONE 4, e4571 (2009).

  3. 3.

    et al. Blood published online, doi:10.1182/blood-2010–05–283523 (23 September 2010).

  4. 4.

    et al. Nature 467, 318–322 (2010).

  5. 5.

    et al. Nat. Biotechnol. 27, 851–857 (2009).

  6. 6.

    et al. Nat. Biotechnol. 26, 808–816 (2008).

  7. 7.

    et al. Genome Res. 20, 1133–1142 (2010).

  8. 8.

    et al. Proc. Natl. Acad. Sci. USA 106, 7571–7576 (2009).

  9. 9.

    & Cell 126, 663–676 (2006).

  10. 10.

    et al. Science 318, 1920–1923 (2007).

Download references

Author information

Affiliations

  1. David A. Williams is at Children's Hospital Boston and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

    • David A Williams
  2. Adrian J. Thrasher is at the Centre for Immunodeficiency, Molecular Immunology Unit, Institute of Child Health, London, UK.

    • Adrian J Thrasher

Authors

  1. Search for David A Williams in:

  2. Search for Adrian J Thrasher in:

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to David A Williams or Adrian J Thrasher.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.1750

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing